220 related articles for article (PubMed ID: 28121555)
21. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
22. Bracing for the biosimilar wave.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):152-154. PubMed ID: 28248938
[No Abstract] [Full Text] [Related]
23. Biosimilars in the Caribbean--key considerations.
Cox SD
West Indian Med J; 2012 Dec; 61(9):849-52. PubMed ID: 24020222
[No Abstract] [Full Text] [Related]
24. Strategic considerations under the Biologics Price Competition and Innovation Act.
Marquardt JL; Auten SR
Expert Opin Ther Pat; 2013 Aug; 23(8):915-8. PubMed ID: 23829693
[TBL] [Abstract][Full Text] [Related]
25. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
26. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
27. The comparability conundrum: biosimilars in the United States, Europe and Canada.
Courage N; Parsons A
Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
[TBL] [Abstract][Full Text] [Related]
28. The Biosimilar Pipeline Seams Seem To Be Bursting.
Reinke T
Manag Care; 2017 Mar; 26(3):24-25. PubMed ID: 28510516
[TBL] [Abstract][Full Text] [Related]
29. Are biosimilars patentable?
Rolfe D; Parker J; Morgan M
Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
[TBL] [Abstract][Full Text] [Related]
30. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy.
Bridges SL; White DW; Worthing AB; Gravallese EM; O'Dell JR; Nola K; Kay J; Cohen SB;
Arthritis Rheumatol; 2018 Mar; 70(3):334-344. PubMed ID: 29411547
[No Abstract] [Full Text] [Related]
31. Biosimilars: the need, the challenge, the future: the FDA perspective.
Epstein MS; Ehrenpreis ED; Kulkarni PM;
Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
[TBL] [Abstract][Full Text] [Related]
32. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
33. Biosimilars.
Bagel J
J Drugs Dermatol; 2014 Jul; 13(7):788-90. PubMed ID: 25007360
[No Abstract] [Full Text] [Related]
34. Encouraging guidance released for biosimilar manufacturers.
Reinke T
Manag Care; 2014 Aug; 23(8):10, 13. PubMed ID: 25225711
[No Abstract] [Full Text] [Related]
35. First biosimilar drug set to enter US market.
Ledford H
Nature; 2015 Jan; 517(7534):253-4. PubMed ID: 25592512
[No Abstract] [Full Text] [Related]
36. Similar or the Same? Why Biosimilars are not the Solution.
Diependaele L; Cockbain J; Sterckx S
J Law Med Ethics; 2018 Sep; 46(3):776-790. PubMed ID: 30336096
[TBL] [Abstract][Full Text] [Related]
37. AMCP Partnership Forum: Biosimilars--Ready, Set, Launch.
J Manag Care Spec Pharm; 2016 Apr; 22(4):434-40. PubMed ID: 27023697
[TBL] [Abstract][Full Text] [Related]
38. On access and accountability--two Supreme Court rulings on generic drugs.
Boumil MM; Curfman GD
N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
[No Abstract] [Full Text] [Related]
39. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020.
Kannappan S; Darrow JJ; Kesselheim AS; Beall RF
Clin Transl Sci; 2021 Sep; 14(5):1917-1923. PubMed ID: 33982425
[TBL] [Abstract][Full Text] [Related]
40. Ancillary Product Patents to Extend Biologic Patent Life.
Goode R; Feldman WB; Tu SS
JAMA; 2023 Dec; 330(21):2117-2119. PubMed ID: 37955940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
